Amoozegar Farnaz, Pringsheim Tamara
Calgary Headache Assessment and Management Program, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Patient Prefer Adherence. 2009 Nov 3;3:251-8. doi: 10.2147/ppa.s6152.
Rizatriptan is a 5HT (IB/ID) agonist with proven efficacy in the acute treatment of migraine headache. We performed a systematic review of the literature for clinical trials of rizatriptan incorporating important patient outcomes including consistency of response, preference, satisfaction, and quality of life. We found evidence that rizatriptan provides consistent relief of migraine attacks and that patients prefer rizatriptan over other treatments because of its speed of relief. Patient satisfaction with rizatriptan is significantly higher than placebo, but appears equivalent to most other triptans. Migraine-specific quality of life at 24 hours is significantly better in patients treated with rizatriptan compared to placebo, while overall long-term quality of life is less affected. The published clinical trials included in this systematic review are subject to bias due to the open-label nature of preference trials and the doses chosen for comparison in head-to-head trials.
利扎曲普坦是一种5HT（IB/ID）激动剂，在偏头痛急性治疗中已证实具有疗效。我们对利扎曲普坦的临床试验文献进行了系统综述，纳入了重要的患者结局，包括反应一致性、偏好、满意度和生活质量。我们发现有证据表明，利扎曲普坦能持续缓解偏头痛发作，且患者因缓解速度快而比其他治疗更偏好利扎曲普坦。患者对利扎曲普坦的满意度显著高于安慰剂，但似乎与大多数其他曲坦类药物相当。与安慰剂相比，接受利扎曲普坦治疗的患者在24小时时偏头痛特异性生活质量显著更好，而总体长期生活质量受影响较小。由于偏好试验的开放标签性质以及头对头试验中选择的比较剂量，本系统综述中纳入的已发表临床试验存在偏倚。
